section name header

Pronunciation ⬇

pra-mi-PEX-ole

Classifications ⬆ ⬇

Therapeutic Classification: antiparkinson agents

Pharmacologic Classification: dopamine agonists

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Stimulates dopamine receptors in the striatum of the brain.
Therapeutic effects:
  • Decreased tremor and rigidity in Parkinson’s disease.
  • Decreased leg restlessness.

Pharmacokinetics ⬆ ⬇

Absorption: >90% absorbed following oral administration.

Distribution: Widely distributed.

Metabolism/Excretion: 90% excreted unchanged in urine.

Half-Life: 8 hr (↑ in geriatric patients and patients with renal impairment).

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown2 hr8 hr
PO-ERunknown6 hr24 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: orthostatic hypotension

Derm: pruritus

Endo: syndrome of inappropriate antidiuretic hormone

GI: constipation, dry mouth, dyspepsia, nausea

GU: urinary frequency

MS: leg cramps, muscle pain, postural deformities, RHABDOMYOLYSIS

Neuro: amnesia, dizziness, drowsiness, hallucinations, weakness, abnormal dreams, aggression, agitation, confusion, delirium, delusions, disorientation, dyskinesia, extrapyramidal syndrome, headache, hypertonia, impulse control disorders (gambling, sexual, uncontrolled spending, binge/compulsive eating), insomnia, paranoid ideation, psychosis, SLEEP ATTACKS, unsteadiness/falling

Misc: tooth disease

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Parkinson's Disease

Renal Impairment

Renal Impairment

Restless Leg Syndrome

Renal Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Mirapex ER

Canadian Brand Names ⬆ ⬇

Mirapex

Code ⬆

NDC Code